Compare Axogen Inc (AXGN) vs Zillow Group Inc Class C (Z) Price & Performance

AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.

The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.

Zillow Group (Z) trades at $33.48, down 0.8% on the day, amid mixed technical signals and ongoing securities litigation. The company shows improving fundamentals with Q2 2026 revenue growth of 18% and consecutive earnings beats, though net margins remain thin at 1.96%. Analyst consensus is divided with a $52 price target representing 55% upside potential from current levels.

While Zillow demonstrates operational improvement and strong monetization growth, significant headwinds include multiple class-action lawsuits and bearish technical indicators. The stock offers substantial upside if legal concerns resolve favorably, but near-term volatility persists due to legal overhang and competitive real estate market pressures.